Kintor Pharmaceutical Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KNTPF research report →
About the company
Kintor Pharmaceutical Limited is a clinical-stage biotechnology firm dedicated to the development and commercialization of a diverse pipeline of small molecule and biologic treatments. Its primary focus is on addressing androgen-receptor-related conditions where current medical options are lacking, serving patients both within the People's Republic of China and globally. The company's innovative pipeline features several key candidates, such as Proxalutamide, a next-generation androgen receptor (AR) antagonist currently being investigated for metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19.
- CEO
- Youzhi Tong
- IPO
- 2020
- Employees
- 168
- HQ
- Suzhou, CN
Price Chart
- Market Cap
- $115.49M
- P/E
- -4.18
- P/S
- 25.55
- P/B
- 4.50
- EV/EBITDA
- -6.31
- Div Yield
- 0.00%
- Gross Margin
- 24.60%
- Op Margin
- -611.29%
- Net Margin
- -601.18%
- ROE
- -98.57%
- ROIC
- -65.91%
- Revenue
- $31.84M · 536.77%
- Net Income
- $-194,943,066 · -25.53%
- EPS
- $-0.43 · -19.44%
- Op Income
- $-197,355,170
- FCF YoY
- 15.08%
- 52W High
- $0.57
- 52W Low
- $0.18
- 50D MA
- $0.33
- 200D MA
- $0.32
- Beta
- -0.55
- Avg Volume
- 265
Get TickerSpark's AI analysis on KNTPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our KNTPF coverage
Recent articles, reports, and earnings notes.
No research on KNTPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KNTPF report →Similar companies
Peers in the same neighborhood.